Skip to main content
Clinical Trials/ACTRN12605000318684
ACTRN12605000318684
Recruiting
Phase 3

A double blind randomised controlled study of the anti-inflammatory effects of clarithromycin 500mg twice daily for 8 weeks in adults with symptomatic Non-Eosinophilic Asthma

Hunter New England Area Health Service0 sites64 target enrollmentSeptember 6, 2005

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Hunter New England Area Health Service
Enrollment
64
Status
Recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 6, 2005
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Symptomatic stable asthma, airway hyperresponsiveness and or bronchodilator response.

Exclusion Criteria

  • Hypersensitivity to Macrolides, Other Respiratory Disease, Taking antihistamine medication, Pregnancy, Breast Feeding, Oral Corticosteroid use in past month, Antibiotic use in past month.

Outcomes

Primary Outcomes

Not specified

Similar Trials